HTATSF1 and breast carcinoma: To evaluate the clinical relevance of these mutations and deletions, we first used the CRISPR/Cas9 system to generate a premature stop codon before the coding sequence of HTATSF1 S748 on genomic DNA in breast cancer cells (Fig. 5C).